

Policy #	Policy Name	Brief Description of Policy Change
UM ONC_1227	Zolinza (vorinostat)	Annual Review
UM ONC_1230	Istodax (romidepsin)	Annual Review
UM ONC_1245	Xofigo (radium Ra 223 dichloride)	Annual Review
UM ONC_1248	Ixempra™(ixabepilone)	Annual Review
UM ONC_1310	Kisqali (ribociclib)	Annual Review
UM ONC_1350	Vittrakvi (larotrectinib)	Annual Review
UM ONC_1351	Xospata (Gilteritinib)	Annual Review
UM ONC_1353	Cablivi (caplacizumab-yhdp)	Annual Review
UM ONC_1354	Daurismo (glasdegib)	Annual Review
UM ONC_1367	Rozlytrek (entrectinib)	Annual Review
UM ONC_1378	Ayvakit (avapritinib)	Annual Review
UM ONC_1380	Gamifant (emapalumab-lzsg)	Annual Review
UM ONC_1383	Sylvant (siltuximab)	Annual Review
UM ONC_1387	Unituxin (dinutuximab)	Annual Review
UM ONC_1396	Koselugo (selumetinib)	Annual Review
UM ONC_1398	Pemazyre (pemigatinib)	Annual Review
UM ONC_1440	Lumakras (sotorasib)	Annual Review
UM ONC_1447	Exkivity (mobocertinib)	Annual Review
UM ONC_1449	Tivdak (tisotumab vedotin-tftv)	Annual Review
UM ONC_1479	Epkinly (epcoritamab-bysp)	Annual Review